<DOC>
	<DOCNO>NCT02657343</DOCNO>
	<brief_summary>Participants breast cancer spread part body , positive protein call HER2 , respond standard treatment . This research study way gain new knowledge combination Ribociclib drug possible treatment diagnosis .</brief_summary>
	<brief_title>An Open-Label , Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor , Ribociclib ( Lee011 ) , In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer .</brief_title>
	<detailed_description>This research study Phase I clinical trial , test safety investigational intervention also try define appropriate dose investigational intervention use study . Ribociclib drug design block certain protein call Cyclin-Dependent Kinases ( CDKs ) require cell divide . These protein may also control ability certain cancer grow . In research study , look safe tolerate dose ribociclib give combination trastuzumab emtansine ( T-DM1 ) . T-DM1 standard treatment patient HER2-positive breast cancer . The FDA ( U.S. Food Drug Administration ) approve Ribociclib treatment disease .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Participants must histologically confirm invasive breast cancer , locally advanced metastatic disease . Patients without pathologic confirmation metastatic disease unequivocal evidence metastasis physical examination radiologic evaluation . The primary tumor , and/or metastasis must test ER , PR HER 2 , HER2 positive define 2013 ASCOCAP guideline . Measureable disease RECIST 1.1 ( least one lesion accurately measure least one dimension &gt; 20mm conventional image technique &gt; 10mm spiral CT MRI ) evaluable disease . Bone lesion ( blastic , lytic , mixed ) absence measurable disease define also acceptable . Prior treatment Cohort A : Prior treatment least one regimen contain Trastuzumab taxane . No prior treatment TDM1 discontinue due disease progression toxicity . No 4 prior line therapy metastatic setting . Cohort B : Must receive prior Trastuzumab , pertuzumab , TDM1 neoadjuvant , adjuvant , metastatic setting . No limit prior line therapy . Age ≥ 18 year . ECOG performance status 02 ( see Appendix A ) Participants must adequate organ bone marrow function define : Absolute neutrophil count ≥1.5 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥ 9 g/dL Total bilirubin &lt; 1.5xULN ; total bilirubin ≤3.0 x ULN direct bilirubin ≤1.5 x ULN patient welldocumented Gilbert 's Syndrome . Serum creatinine ≤ 1.5 mg/dL calculate GFR ≥ 50mL/min ALT/AST &lt; 2.5x ULN ; liver metastasis , ALT/AST ≤5.0x ULN INR ≤ 1.5 Potassium , total calcium ( correct serum albumin ) , magnesium , sodium phosphorus within normal limit institution correct within normal limit supplement first dose study medication Biopsies : Cohort B : patient disease deem treat investigator safely accessible biopsy require undergo research biopsy outline protocol . Cohort A : Such biopsy optional . A negative serum pregnancy test ≤ 72 hour start study treatment premenopausal woman woman &lt; 1 year onset menopause . Ability understand willingness sign write informed consent document . Participants must able swallow Ribociclib capsule . Patients must screen standard 12lead ECG mean value meet follow parameter : QtcF interval screen &lt; 450msec ( use Friderica 's correction ) Resting heart rate 5090bpm Participants chemotherapy within 14 day prior registration recover toxicity relate prior anticancer therapy NCICTCAE version 4.03 Grade ≤1 ( Exception criterion : patient grade alopecia allow enter study ) . There washout period require Trastuzumab . Participants receive radiotherapy ≤ 2 week prior start study drug , recover grade 1 well related side effect therapy ( except alopecia neuropathy ) and/or ≥ 25 % bone marrow irradiate . Participants previously receive CDK 4/6 inhibitor . Participants central nervous system ( CNS ) involvement unless meet ALL follow criterion : At least 4 week prior therapy completion ( include radiation and/or surgery ) start study treatment Clinically stable CNS tumor time screen receive steroid and/or enzymeinducing antiepileptic medication brain metastasis . History allergic reaction attribute compound similar chemical biologic composition ribociclib , TDM1 ( Cohort A ) and/or Trastuzumab ( Cohort B ) . In general , use concomitant medication deem necessary care patient permit study , except specifically prohibit . Combination administration study drug could result drugdrug interaction ( DDI ) could potentially lead reduced activity enhance toxicity concomitant medication and/or Ribociclib . Patient currently receive follow medication discontinue use within 7 day prior start study drug ( see ( Tables 1 2 , Appendix B detail ) : Known strong inducer inhibitor CYP3A4/5 , include grapefruit , grapefruit hybrid , pummelo , starfruit , Seville oranges That narrow therapeutic window predominantly metabolize CYP3A4/5 Herbal preparations/medications , dietary supplement . The list provide ( Tables 1 2 , Appendix B ) comprehensive meant use guide . The list base Oncology Clinical Pharmacology DrugDrug Interaction Database ( release date : 29 Oct 2012 ) , compile Indiana University School Medicine 's P450 Drug Interaction Table . http : //medicine.iupui.edu/clinpharm/ddis/maintable/ ) supplement FDA Draft Guidance Industry , Drug Interaction Studies Study Design , Data Analysis , Implications Dosing Labeling ( February 2012 ) ( http : //www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf ) , University Washington 's Drug Interaction Database ( http : //www.druginteractioninfo.org/ ) . For current list medication may cause QT prolongation and/or torsades de pointes ( TdP ) , refer CredibleMeds® website ( http : //crediblemeds.org/ ) . Participants concurrent severe and/or uncontrolled medical condition would , investigator 's judgment , cause unacceptable safety risk , contraindicate patient participation clinical trial compromise compliance protocol ( e.g . chronic pancreatitis , chronic active hepatitis , active untreated uncontrolled fungal , bacterial viral infection , etc. ) . Participants major surgery within 2 week prior start study drug recover major side effect ( tumor biopsy consider major surgery ) . Participants clinically significant , uncontrolled heart disease and/or cardiac repolarization abnormality include follow : History acute coronary syndrome ( include myocardial infarction , unstable angina , coronary artery bypass grafting , coronary angioplasty , stenting ) symptomatic pericarditis within 6 month prior screen History document congestive heart failure ( New York Heart Association functional classification IIIIV ) Clinically significant cardiac arrhythmia ( e.g . ventricular tachycardia ) , complete leave bundle branch block , highgrade AV block ( e.g . bifascicular block , Mobitz type II thirddegree AV block Documented cardiomyopathy Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % determined Multiple Gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) screen Long QT syndrome family history idiopathic sudden death congenital long QT syndrome , follow Risk factor Torsades de Pointe ( TdP ) include uncorrected hypokalemia hypomagnesemia , history cardiac failure , history clinically significant/symptomatic bradycardia . Inability determine QT interval screening ( QTcF , use Fridericia 's correction ) Systolic blood pressure ( SBP ) &gt; 160 mmHg &lt; 90 mmHg screen Known history HIVpositivity . Active Hepatitis B and/or Hepatitis C Infection Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , uncontrolled ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . Concurrent malignancy malignancy within 3 year prior start study drug , exception adequately treat basal squamous cell carcinoma , nonmelanomatous skin cancer curatively resect cervical cancer . Participants malignancies less 3 year prior registration may consider eligible discussion principle investigator . Participants currently receive receive systemic corticosteroid ≤2 week prior start study drug , fully recover side effect treatment . The following us corticosteroid permit : single dos , topical application ( e.g. , rash ) , inhale spray ( e.g. , obstructive airway disease ) , eye drop local injection ( e.g. , intraarticular ) . Patient currently receive warfarin coumarinderived anticoagulant treatment , prophylaxis otherwise . Therapy heparin , low molecular weight heparin ( LMWH ) fondaparinux allow . Participation prior investigational study within 30 day prior enrollment within 5 halflives investigational product , whichever longer . Patient ChildPugh score B C. Participants history noncompliance medical therapy . Pregnant woman exclude study Ribociclib potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother Ribociclib , breastfeed discontinue mother treated Ribociclib . These risk also apply Trasutuzumab use study . Pregnancy define state female conception termination gestation , confirm postitive hCG laboratory test ( &gt; 5 mIU/mL ) . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception throughout study 8 week study drug discontinuation . Highly effective contraception method include : Total abstinence line prefer usual lifestyle patient . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment Male sterilization ( least 6 month prior screen ) . For female patient study , vasectomize male partner sole partner patient Combination two follow Placement intrauterine device ( IUD ) intrauterine system ( IUS ) Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/ vaginal suppository . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . Sexually active male unless use condom intercourse take drug 4 month stop treatment father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer With Positive HER2</keyword>
</DOC>